Marc Beer Advancing the Fight against Pelvic Floor Disorder at Renovia
Renovia Inc is now set for the development of several new products. This is after the firm secured a second round of funding from investors in the healthcare industry. The amount that the firm was able to raise in the Series B financing amounted to 42 million dollars of which 32.3 million dollars was from Series B equity and a venture debt of 10 million dollars. The funds will be directed towards research and development of Pelvic floor disorders products.
Renovia Inc. is a Boston based medical technology company that was co-founded in 2016 by Marc Beer, Yolanda Lorie, and Ramon Iglesias, MD. At the firm, Beer doubles up as the Chairman and CEO. The firm specializes in the creation of various innovative diagnostic and therapeutic products that aid in the treatment of pelvic floor disorders like urinary incontinence. Pelvic floor disorder is a condition that only affects women and based on statistics more than 250 million women globally are already affected by the disease. Renovia Inc. for the more than two years it has been on operation has achieved a lot in the healthcare industry. Among its many achievements in April of 2018 Renovia first product Leva received a clean bill of health from FDA and is now available in the market.
Those that came on board to support Renovia Inc on this milestone funding include Renovia long time investment partners Longwood Fund. The other group of investment companies includes New York-based Perceptive Advisors and Ascension Ventures of Missouri. Beer acknowledged the immense support that the three healthcare investment firms provided to Renovia Inc and thanked them for agreeing to come on board and share in the firm’s vision of delivering better diagnosing and treating pelvic floor disorder that affects millions of women globally. Beer added besides the funding pelvic floor disorder patients stands to gain a lot from the firms’ technological partnership. Among the things that pelvic floor disorder patients stand to benefit from the partnership include valuable data that will inform them of new treatment options, greater knowledge, and understanding of the condition and in the long run lower healthcare cost.
Marc Beer, the CEO of Renovia Inc, is a seasoned serial entrepreneur with more than two decades of commercialization and development experience in industries such as biotechnology, pharmaceuticals and devices industries among others. Among the many firms that Beer helped established is ViaCell where he served as CEO IN 2002. ViaCell is a biotechnology firm that specializes in the use of human cells to provide custom cures. Beer has also served in various capacities in the sales department at Abbott Laboratories. As a consultant Beer provided consultation services to top healthcare firms and among them is OvaScience(Nasdaq: OVAS). Learn more: https://ideamensch.com/marc-beer/